CenterBook Partners LP Lowers Holdings in argenex SE $ARGX

CenterBook Partners LP trimmed its position in shares of argenex SE (NASDAQ:ARGX) by 83.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,823 shares of the company’s stock after selling 14,532 shares during the quarter. CenterBook Partners LP’s holdings in argenex were worth $2,082,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of argenex by 91.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock valued at $6,511,000 after purchasing an additional 4,217 shares during the period. Allianz Asset Management GmbH boosted its holdings in shares of argenex by 21.3% in the third quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock worth $2,708,000 after buying an additional 645 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in argenex by 14.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 211,330 shares of the company’s stock valued at $162,160,000 after buying an additional 26,343 shares during the period. Alta Wealth Advisors LLC purchased a new stake in argenex during the third quarter valued at approximately $623,000. Finally, Voya Investment Management LLC increased its holdings in argenex by 36.3% during the third quarter. Voya Investment Management LLC now owns 21,610 shares of the company’s stock valued at $15,939,000 after buying an additional 5,755 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenex Price Performance

argenex stock opened at $847.26 on Friday. argenex SE has a 1 year low of $510.05 and a 1 year high of $934.62. The firm’s 50 day moving average price is $831.90 and its 200-day moving average price is $804.81. The stock has a market cap of $52.43 billion, a P/E ratio of 36.38, a PEG ratio of 0.73 and a beta of 0.37.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. DZ Bank upgraded argenex to a “strong-buy” rating in a research note on Friday, December 19th. Wells Fargo & Company upped their price target on argenex from $1,264.00 to $1,317.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Wall Street Zen cut argenex from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Truist Financial increased their target price on shares of argenex from $950.00 to $1,030.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Finally, Piper Sandler raised their target price on shares of argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $986.78.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.